These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37304292)

  • 1. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
    Lin C; Xu G; Gao S; Feng T; Li S
    Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Chen HW; Kuo YW; Chen CY; Chang CH; Wang SM; Chien YC; Lu WC; Chen JP; Chang CY; Wei YF; Chang SC; Shu CC; Wang JY; Liao WY; Wang HC; Yu CJ
    Oncologist; 2024 Apr; 29(4):e498-e506. PubMed ID: 38227604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.
    Stroh GR; Peikert T; Escalante P
    Cancer Immunol Immunother; 2021 Nov; 70(11):3105-3111. PubMed ID: 33770211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.
    Fujita K; Elkington P; Redelman-Sidi G; Kanai O; Yamamoto Y; Imakita T; Okamura M; Nakatani K; Mio T
    Cancer Immunol Immunother; 2022 Nov; 71(11):2757-2764. PubMed ID: 35429244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
    Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
    BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.
    Wyndham-Thomas C; Dirix V; Schepers K; Martin C; Hildebrand M; Goffard JC; Domont F; Libin M; Loyens M; Locht C; Van Vooren JP; Mascart F
    BMC Infect Dis; 2015 Feb; 15():59. PubMed ID: 25886172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.
    Bae S; Kim YJ; Kim MJ; Kim JH; Yun SC; Jung J; Kim MJ; Chong YP; Kim SH; Choi SH; Kim YS; Lee SO
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34521732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis.
    Krutikov M; Faust L; Nikolayevskyy V; Hamada Y; Gupta RK; Cirillo D; Mateelli A; Korobitsyn A; Denkinger CM; Rangaka MX
    Lancet Infect Dis; 2022 Feb; 22(2):250-264. PubMed ID: 34606768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors and Tuberculosis Infection in Lung Cancer: A Case Series and Systematic Review With Pooled Analysis.
    He Y; Peng D; Liang P; Long J; Liu A; Zeng Z
    J Clin Pharmacol; 2023 Apr; 63(4):397-409. PubMed ID: 36309847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of IGRA researches].
    Ariga H; Harada N
    Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.
    Blount RJ; Tran MC; Everett CK; Cattamanchi A; Metcalfe JZ; Connor D; Miller CR; Grinsdale J; Higashi J; Nahid P
    BMC Public Health; 2016 Aug; 16(1):875. PubMed ID: 27558397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance between TST and QFT-TBGold Plus for Latent Tuberculosis Screening among Under-Five Children: An Interim Analysis.
    Surve S; Bhor V; Naukariya K; Begum S; Munne K; Tipre P; Sutar N; Jaiswal A; Bhonde G; Chauhan S; Shah I
    J Trop Pediatr; 2021 Dec; 67(6):. PubMed ID: 34904674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany.
    Thee S; Krüger R; von Bernuth H; Meisel C; Kölsch U; Kirchberger V; Feiterna-Sperling C
    PLoS One; 2019; 14(5):e0216234. PubMed ID: 31112542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.
    Hirano S; Takahashi H; Nakamura S; Matsuda K; Ishikawa R; Tamura K; Shikano K; Fujita T; Amano H; Nakamura M
    Chin Clin Oncol; 2024 Jun; 13(3):43. PubMed ID: 38859608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commercially available CD4 + and CD8 + IFN-γ release assays combined with an HBHA-induced IGRA improve the characterization of the tuberculosis spectrum and monitoring of treatment in children.
    Buonsenso D; Delogu G; Del Carmen Pereyra Boza M; De Maio F; Palucci I; Martino L; Pata D; Sanguinetti M; Valentini P; Sali M
    Eur J Pediatr; 2023 May; 182(5):2155-2167. PubMed ID: 36847873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lessons learned from tuberculosis outbreak cases].
    Kato S; Kuwabara K
    Kekkaku; 2014 Feb; 89(2):77-88. PubMed ID: 24716362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined IFN-γ and TNF-α release assay for differentiating active tuberculosis from latent tuberculosis infection.
    Kim JY; Park JH; Kim MC; Cha HH; Jeon NY; Park SY; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH
    J Infect; 2018 Oct; 77(4):314-320. PubMed ID: 29746954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.